Journal
CANCER TREATMENT REVIEWS
Volume 38, Issue 4, Pages 272-283Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2011.06.004
Keywords
Ovarian cancer; Angiogenesis; Clinical trials; VEGF; PDGF; FGF; Angiopoietin
Categories
Funding
- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)
Ask authors/readers for more resources
Results of standard chemotherapy in ovarian cancer are hampered by the development of drug resistance leading to disease recurrence. This prompted interest in the development of therapies targeting critical pathways responsible for tumor progression. Angiogenesis is a key process that enables ovarian cancer growth and metastasis in the peritoneal space. Its regulation relies on signaling mechanisms initiated by the vascular endothelial growth factor, the platelet-derived growth factor, the fibroblast growth factor, angiopoietins, and others. These pathways are not only important to the modulation of the tumor microenvironment and vasculature, but also control cancer cell proliferation and survival. In this review, we discuss preclinical evidence supporting the rationale for inhibiting these pathways and provide an overview for the clinical development of agents targeting them. Clinical trials evaluating such agents alone and in combination with chemotherapy are ongoing. Early clinical results position antiangiogenic therapy at the forefront of change to the standard treatment of difficult to treat ovarian cancer. (c) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available